This generally well-conducted review concluded that the prevalence of biopsy-proved celiac disease in individuals meeting the IBS diagnostic criteria is approximately 4% and the odds for biopsy-proved celiac disease is more than fourfold that in healthy controls. Interpretation of the results should be undertaken with some caution due to the limitations of the included studies and the between study heterogeneity. criteria; sample size ranged from 100 to 1,200). Seven studies were case series and seven studies were case control studies. Only four of the included studies reported recruiting consecutive patients.
Authors' objectives
To estimate the prevalence of celiac disease in adults who met the diagnostic criteria for irritable bowel syndrome (IBS).
Searching MEDLINE (1950 to May 2008 and EMBASE (1980 to May 2008 were searched without language restrictions. Search terms were reported. Conference proceedings (2000 to December 2007) and bibliographies of relevant studies were also searched.
Study selection
Case series and case-control studies with at least 90 unselected adults with a presumed diagnosis of IBS, which tested for celiac disease using serological tests in all enrolled individuals, were eligible for inclusion. Included studies were primarily conducted in Europe. Settings included primary and secondary care and population based studies. Tests used to diagnose celiac disease were endomysial antibody (EMA), IgA-class antigliadin antibody (AGA), tissue transglutaminase antibody (tTGA) and/or distal duodenal biopsy.
Two reviewers independently selected studies for the review. It was not reported how disagreements were resolved.
Assessment of study quality
The authors did not state that they assessed study quality. However, the authors reported whether patients were recruited consecutively and the potential for spectrum bias in diagnostic case-control studies was discussed.
Data extraction
The number of patients with positive serological tests was extracted and expressed as a percentage of the total. Odds ratios (OR) and 95% confidence intervals (CI) were calculated for serological or biopsy positive patients compared to control patients.
Two reviewers independently extracted data and discrepancies were resolved by consensus.
Methods of synthesis
A pooled prevalence of celiac disease was calculated by combining the percentage of patients meeting the IBS criteria with positive serological test or biopsy results from the case series and case-control studies. If a study reported no positive serological test or biopsy results, 0.5 was added to all four cells of the 2x2 table. Sensitivity analyses were conducted to investigate setting, geographic region, the IBS diagnostic criteria used, and the IBS sub-type. Individual subgroups were compared using the Cochrane Q test. Pooled OR and 95% CI were calculated using a random effects model. it was not reported how heterogeneity was assessed in these analyses. Publication bias was assessed for casecontrol studies using funnel plots and the Egger test.
